Copyright
©The Author(s) 2023.
World J Cardiol. Jan 26, 2023; 15(1): 23-32
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.23
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.23
Table 2 Outcomes based on primary and secondary endpoints in the two study groups
Clinical outcome | Routine (n = 183) | Delayed (n = 154) | P value |
Primary endpoints, n (%) | |||
MACCE | 16 (8.7) | 20 (12.9) | 0.152 |
Secondary endpoints, n (%) | |||
Death | 5 (2.7) | 3 (1.9) | 0.732 |
Myocardial infarction | 2 (1.1) | 7 (4.5) | 0.085 |
Target vessel revascularization | 3 (1.6) | 3 (1.9) | 0.999 |
Congestive heart failure | 6 (3.3) | 7 (4.5) | 0.547 |
Stroke | 0 | 0 | 0.999 |
Angina | 4 (2.2) | 1 (0.6) | 0.381 |
Dyspnea | 6 (3.3) | 5 (3.2) | 0.999 |
Major Bleeding1 | 1 (0.5) | 3 (1.9) | 0.335 |
- Citation: Sethi R, Mohan L, Vishwakarma P, Singh A, Sharma S, Bhandari M, Shukla A, Sharma A, Chaudhary G, Pradhan A, Chandra S, Narain VS, Dwivedi SK. Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction. World J Cardiol 2023; 15(1): 23-32
- URL: https://www.wjgnet.com/1949-8462/full/v15/i1/23.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i1.23